title: Innovative financing for late-stage global health research and development: the Global Health Investment Fund.
abstract: Innovative financing strategies for global health are urgently needed to reinvigorate investment and new tools for impact. Bottleneck areas along the research and development (R&D) pipeline require particular attention, such as the transitions from preclinical discovery to clinical study, and product development to implementation and delivery. Successful organizations mobilizing and disbursing resources through innovating financing mechanisms include UNITAID, the Global Fund, and Gavi, the Vaccine Alliance. Although precise numbers are poorly documented, estimated investment in low-income settings falls seriously short of local need. This commentary discusses the newly established Global Health Investment Fund as a case study to support late-stage global health R&D.
authors.affiliation: Harvard School of Public Health, Boston, MA, UK joseph.fitchett@mail.harvard.edu.
authors.forename: Joseph Robert
authors.initials: JR
authors.lastname: Fitchett
authors.affiliation: Seven Bridges Genomics, London, UK.
authors.forename: Julia
authors.initials: J
authors.lastname: Fan Li
authors.affiliation: Harvard School of Public Health, Boston, MA, UK.
authors.forename: Rifat
authors.initials: R
authors.lastname: Atun
mesh_terms: D003906:Developing Countries; D005376:Financial Management; D014943:Global Health; D006801:Humans; D007391:International Cooperation; D012106:Research / Q000191:economics*
keywords: Diagnostics; Global health; Innovating financing; Research and development; Therapeutics; Vaccines